The CARDIOPROTECT Trial (NCT07654426) | Clinical Trial Compass
Not Yet RecruitingPhase 2
The CARDIOPROTECT Trial
United States60 participantsStarted 2026-10-02
Plain-language summary
This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care R-CHOP or pola-R-CHP treatment regiments.
The names of the study drugs involved in this study are:
* Dexrazoxane (a type of Topoisomerase II Inhibitor)
* Liposomal Doxorubicin (a type of Topoisomerase II Inhibitor)
* Standard of care R-CHOP treatment regimen (Cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab)
* Standard of care pola-R-CHP treatment regimen: Cyclophosphamide, doxorubicin, polatuzumab vedotin-piiq, prednisone, rituximab
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. LVEF 30-50% on most recent echocardiogram with or without HF history
. LVEF 50% with a history of HF (i.e. HF with improved EF or HF with preserved EF).
. History of anthracycline exposure for different malignancy.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial is focused on protecting heart function during DLBCL treatment and is measuring Left Ventricular Ejection Fraction, does my current heart health make me a good or poor candidate for something like this?
2This is a Phase 2 trial that hasn't started recruiting yet — what does that mean for how much is already known about its safety and whether it actually works, compared to just going with standard DLBCL treatment now?
3Because the trial is measuring LVEF, can you explain what cardiotoxicity risk I already face from standard DLBCL chemotherapy like R-CHOP, and how serious that risk is in my specific situation?
4Since the trial isn't recruiting yet, would it make sense to start standard treatment now and potentially revisit this trial later, or could waiting to join it affect my lymphoma outcomes?
5What kinds of extra heart monitoring or clinic visits would likely be involved in a cardioprotection trial like this, and is that something that would realistically fit into my schedule and life right now?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Left Ventricular Ejection Fraction (LVEF)
Timeframe: LVEF will be assessed by echocardiography 3 months after completion of front-line chemotherapy, with chemotherapy administered for up to 18 weeks.